Summary
Twenty-six patients with advanced, measurable epithelial carcinoma of the ovary were treated with 76 courses of esorubicin at doses ranging from 20–30 mg/m2 every 3 weeks. All patients are evaluable for toxicity and response. All patients had received prior therapy including radiation therapy in 9, non-anthracycline chemotherapy in 25, and surgery in 25. All patients were GOG performance status 0, 1 or 2. Two partial responses were seen. Severe (grade 3 or 4) leukopenia, thrombocytopenia, and anemia were seen in 13, 1 and 4 patients, respectively. Moderate gastrointestinal toxicity was also noted. Alopecia and mucositis were rare. Phlebitis was not seen. Neither clinical congestive cardiomyopathy nor decrement in left ventricular ejection fraction was observed. We conclude that using this dose and schedule of esorubicin as second-line chemotherapy in ovarian epithelial neoplasms lacks significant activity and is associated with moderate toxicity.
Similar content being viewed by others
References
Arcamone F, Penco S, Redaelli S, Hanessian S: Synthesis and antitumor activity of 4′-deoxydaunorubicin and 4′-deoxyadriamycin. J Med Chem 19(12): 1424–1425, 1976
Salmon SE, Young L, Soehulen B, Liu R: Antitumor activity of esorubicin in human tumor clonogenic assay with comparison to doxorubicin. J Clin Oncol 2:282–286, 1984
Giuliani FC, Kaplan NO: New doxorubicin analogs active against doxorubicin resistant colon tumor xenograft in the nude mouse. Cancer Res 40:4682–4687, 1980
Casazza AM, Savi G, Pratesi G, DiMarco A: Antitumor activity in mice of 4′-deoxydoxorubicin in comparison to doxorubicin. Eur J Cancer Clin Oncol 19:411–418, 1983
Villani F, Comazzi R, Genitoni V: Preliminary evaluation of myocardial toxicity of 4′-deoxydoxorubicin: Experimental and clinical results. Drugs Explt Clin Res 3:223–231, 1985
Rozencweig M, Crespeigne N, Kenis Y: Phase I trial with 4′-deoxydoxorubicin (esorubicin). Invest New Drugs 1(4): 309–313, 1983
Garewal HS, Robertone A, Salmon SE, Jones SE, Alberts DS, Brooks R: Phase I trial of esorubicin (4′-deoxydoxorubicin). J Clin Oncol 2(9):1034–1039, 1984
Locker GY, Hoeltgen T, Kilton L, Krauss S, McNamara M, Blough R, Johnson C: Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: An Illinois Cancer Council trial. Cancer Treat Rep 71(7):765–766, 1987
Carlson RW, Billingham ME, Kohler M, Johnson FD, Doroshow JH, Torti FM: Esorubicin in refractory metastatic carcinoma of the breast: A Northern California Oncology Group study. Cancer Treat Rep 71(4):427–428, 1987
Zagonel V, Tirelli U, Vaccher E, Sorio R, Saracchini S, Monfardini S: Activity of 4′ -deoxydoxorubicin (esorubicin) in patients with plasma cell tumors: A phase II study. Invest New Drugs 5:123, 1987
Kris MG, Gralla RJ, Burke MT, Fiore JJ, Kelsen DP, Marks LD, Heelan RT: Phase II trial of esorubicin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 71(7):783–784, 1987
Frustaci S, Gasparini G, Veronesi A, Tirelli U, Pacciarini MA, Crivellari D, Zagonel V, Monfardini S: Phase II study of esorubicin (4′ -deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma. Invest New Drugs 5:307–309, 1987
Braich T, Ahmann FR, Garewal HS, Robertone A, Salmon SE: Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer. Invest New Drugs 4(2):193–196, 1986
Carlson RW, Williams RD, Billingham ME, Kohler M, Torti F: Phase II trial of esorubicin in the treatment of metastatic carcinoma of the kidney: A study of the Northern California Oncology Group. Cancer Treat Rep 71(7):767–768, 1987
Frustaci S, Gasparini G, Galligioni E, Tirelli U, Di Pietro N, Crivellari D, Lo Re G, Monfardini S: Phase II trial of esorubicin in patients with advanced melanoma. Cancer Treat Rep 3, 71:325–326, 1987
Ringenberg S, Propert K, Perry M, Weiss RB, Modeas C, Richards F, Graziano S, Hirsh V, Green M: Clinical cardiotoxicity of esorubicin: A prospective study with serial gaited heart scans and report of selected cases. Pro Am Soc Clin Oncol 6:83, 1987
Young RC, Ozols RF, Myers CE: The anthracycline antineoplastic drugs. N Engl J Med 305:139–153, 1981
Hubbard SM, Varkes P, Young RC: Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy. Cancer Treat Rep 62:1375–1377, 1978
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McGuire, W.P., Blessing, J.A. & Berman, M.L. Phase II study of esorubicin (4′-deozydoxorubicin) in advanced epithelial carcinoma of the ovary: A Gynecologic Oncology Group study . Invest New Drugs 7, 333–336 (1989). https://doi.org/10.1007/BF00173763
Issue Date:
DOI: https://doi.org/10.1007/BF00173763